Herman Steen, Chief Executive Officer, Co-founder
Herman Steen holds a PhD in pharmacology from the University of Groningen in 1992. He worked at Byk Gulden (Altana Pharma/Nycomed/Takeda) on clinical research positions in the gastro-intestinal and respiratory area. In 1998 he founded PharmaScope, a clinical contract research and pharma recruitment organization. After selling PharmaScope to Quintiles Transnational Corp., the international operating Orphan drug CRO PSR Group was established. Dr. Steen has extensive experience in clinical research and as a pharma-biotech serial-entrepreneur he is heavily involved in commercialization and bridging the pre-clinical research into the clinic.
Guus van Scharrenburg, Chief Operations Officer
Guus van Scharrenburg was trained as a biochemist. After obtaining his PhD ( cum laude) at the University of Utrecht by studying the structure-function relationship of lipolytic enzymes he immediately joined the pharmaceutical industry. Currently he has over more than 25 years of experience in the pharmaceutical industry (Solvay, Abbott) with responsibility for programs and projects in all R&D phases. During his career he was responsible for R&D alliances with big Pharma partners as well as smaller innovative biotechs. He was Head of Biotechnology of Solvay in Weesp (NL) and Global Project Director of the Solvay -Bristol-Myers Squibb alliance for development of CB1 antagonists. The last 5 years he was involved in neurology research programs, responsible for phase II and III development projects for cardio-metabolic and neurology indications, respectively.
Emil Pot, General Counsel, Chief Business Officer
Emil holds a Master of Laws degree from the University of Groningen, he obtained a training in life sciences within the Flanders Institute for Biotechnology (VIB, Belgium), and he is a registered European Patent Attorney (EPA). At BiOrion, Emil is holding the position of General Counsel, responsible for Business Development, Legal and IP. Before BiOrion, he co-founded the Belgian biotech company ActoGeniX NV and also held the position of General Counsel. He was involved in the different financing rounds (totaling €45M), and actively contributed to the successful exit with the acquisition by Intrexon Inc. Between 1994 and 2005, Emil held various business development and technology transfer positions at VIB and the University of Groningen (The Netherlands
Marcel Akkerman, Chief Financial Officer
Marcel Akkerman obtained his qualification for Registered Auditor at NIVRA, The Netherlands. He worked for over 20 years at EY at several (senior) management positions in the audit assurance practice. He has a strong focus on financial institutions, investment companies and real estate property companies including complex consolidations and valuation issues. In that position he was managing client portfolios with ultimate responsibilities regarding profit, technical coordination and reporting aspects. After EY he has worked for five years at Citco Group as Group Internal Auditor responsible for internal audits for Citco Group worldwide and works as external adviser for Vesteda Investment Management, responsible for process management and in-control certification